// App-Quantinova.ai

3729 : Chronic Myeloid Leukemia Patients Undergoing Interferon Alpha Therapy Exhibit Normal Peripheral Blood Gamma Delta T Cells That May Be Expanded in Vitro to Generate Predominantly CD45RA-Positive Effector Memory Cells for Immunotherapy

Researchers

Presenter

  • Anna Kreutzman

Principal Investigators

  • Mette Matilda Ilander

  • Satu Mustjoki

  • Lynne Marie Postovit

Medical Centers

  • Hematology Research Unit Helsinki, Department of Medicine, University of Helsinki and Helsinki University Central Hospital (HUCH), Helsinki, Finland

  • Hematology Research Unit Helsinki, Department of Medicine, University of Helsinki and Helsinki University Central Hospital (HUCH), Helsinki, Finland

  • Hematology Research Unit, Biomedicum Helsinki, Helsinki University Central Hospital HUCH, Helsinki, Finland

  • Cell Biology and Anatomy, Western University, London, ON, Canada,

Locations

  • Finland

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Peripheral blood mononuclear cell

  • Interferon

  • Natural killer group 2D

Drug/Treatment

  • Interferon alpha

  • IFN-lambda

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved